In This Article:
TORONTO, Feb. 29, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces that it will present new data demonstrating the potential of its proprietary NetraAI clinical trial solution to generate novel insights into key drivers of Parkinson's disease (PD). The data will be presented in a poster at AD/PD™ 2024 (the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders), which is taking place March 5-9 in Lisbon, Portugal.
"PD is a complex and debilitating disease, and patients living with it have an urgent need for novel treatment options," said Dr. Joseph Geraci, PhD, Founder and Chief Technology Officer of NetraMark. "Key to achieving this critical goal is advancing our understanding of the biological markers and pathways that contribute to development and progression of the disease. We look forward to sharing the latest PD insights that NetraAI has generated at the conference."
Poster Presentation Information
Title: Using NetraAI to Discover Parkinson's Disease Subtypes: Generative AI Reveals Transcriptomic Personas Linking Mitochondrial, Microbiome, and Immune Signaling
Date and Time: Friday March 8 - Saturday March 9, 2024
Poster Board #: 0598
About NetraAI
In contrast with other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) that can significantly increase the chances of a clinical trial success. Other AI methods lack these focus mechanisms and assign every patient to a class, even when this leads to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.